Non-myeloablative allogeneic transplantation - State-of-the-art

Pediatric Transplantation

Volumn 8, Issue SUPPL. 5, 2004, Pages 12-18

  Storb, Rainer ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Graft versus host disease; Graft versus tumor effect; Mixed hematopoietic chimerism; Non myeloablative hematopoietic cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; BISMUTH 213; CYCLOSPORIN; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOABLATIVE AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILDHOOD CANCER; CHILDHOOD DISEASE; CHIMERA; CONFERENCE PAPER; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL RESEARCH; NONHUMAN; OUTCOMES RESEARCH; RADIATION DOSE; T LYMPHOCYTE; WHOLE BODY RADIATION;

ANIMALS; CLINICAL TRIALS; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 2942750391     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-2265.2004.00189.x     Document Type: Conference Paper

References (37)

1. MOLINA AJ, STORB RF. Hematopoietic stem cell transplantation in older adults. In: ROWE JM, LAZARUS HM, CARELLA AM, eds. Handbook of Bone Marrow Transplantation, 1st edn. London: Martin Dunitz Ltd, 2000: pp. 111-137.
2. SLAVIN S, NAGLER A, NAPARSTEK E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998: 91: 756-763.
3. GIRALT S, ESTEY E, ALBITAR M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997: 89: 4531-4536.
4. MCSWEENEY P, NIEDERWIESER D, SHIZURU J, et al. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine (CSP) and mycophenolate mofetil (MMF). Blood 1999: 94(Suppl. 1): 393a, 1742 (abstract).
5. FEINSTEIN L, SANDMAIER B, MALONEY D, et al. Nonmyeloablative hematopoietic cell transplantation: Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann NY Acad Sci 2001: 938: 328-339.
6. MCSWEENEY PA, NIEDERWIESER D, SHIZURU JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001: 97: 3390-3400.
7. KHOURI IF, KEATING M, KÖRBLING M, et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998: 16: 2817-2824.
8. STORB R, YU C, MCSWEENEY P. Mixed chimerism after transplantation of allogeneic hematopoietic cells. In: THOMAS ED, BLUME KG, FORMAN SJ, eds. Hematopoietic Cell Transplantation, 2nd edn. Boston: Blackwell Science, 1999: pp. 287-295.
9. CARELLA AM, CHAMPLIN R, SLAVIN S, MCSWEENEY P, STORB R. Mini-allografts: Ongoing trials in humans (Editorial). Bone Marrow Transplant 2000: 25: 345-350.
10. SPITZER TR, MCAFEE S, SACKSTEIN R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000: 6: 309-320.
11. SYKES M, PREFFER F, MCAFEE S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999: 353: 1755-1759.
12. CHILDS R, CHERNOFF A, CONTENTIN N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000: 343: 750-758.
13. CHILDS R, CLAVE E, CONTENTIN N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 1999: 94: 3234-3241.
14. STORB R, YU C, WAGNER JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997: 89: 3048-3054.
15. STORB R, YU C, BARNETT T, et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999: 94: 1131-1136.
16. STORB R, YU C, ZAUCHA JM, et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA41g, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood 1999: 94: 2523-2529.
17. YU C, STORB R, MATHEY B, et al. DLA-identical bone marrow grafts after low-dose total body irradiation: Effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 1995: 86: 43764381
18. NIEDERWIESER D, MARIS M, SHIZURU JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003: 101: 1620-1629.
19. FEINSTEIN LC, SANDMAIER BM, HEGENBART U, et al. Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. Br J Haematol 2003: 120: 281-288.
20. GEORGES GE, STORB R, THOMPSON JD, et al. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood 2000: 95: 3262-3269.
21. BETHGE WA, WILBUR DS, STORB R, et al. Selective T-cell ablation with bismuth-213 labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood 2003: 101: 5068-5075.
22. MARIS M, STORB R. The transplantation of hematopoietic stem cells after nonmyeloablative conditioning: A cellular therapeutic approach to hematologic and genetic diseases. Immunol Res 2003: 28: 13-24.
23. MARIS MB, NIEDERWIESER D, SANDMAIER BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003: 102: 2021-2030.
24. MALONEY DG, MOLINA AJ, SAHEBI F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003: 102: 3447-3454.
25. SANDMAIER BM, MALONEY DG, GOOLEY T, et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies: Clinical results of a TBI-based conditioning regimen. Blood 2001: 98(Part 1): 742a-743a, 3093 (abstract).
26. MARIS M, NIEDERWIESER D, SANDMAIER B, et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT. Blood 2001: 98(Part 1): 858a, 3563 (abstract).
27. WEISSINGER F, SANDMAIER BM, MALONEY DG, BENSINGER WI, GOOLEY T, STORB R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood 2001: 98: 3584-3588.
28. JUNGHANSS C, MARR KA, CARTER RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. Biol Blood Marrow Transplant 2002: 8: 512-520.
29. JUNGHANSS C, BOECKH M, CARTER RA, et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002: 99: 1978-1985.
30. XUN CQ, MCSWEENEY PA, BOECKH M, STORB RF, BROUDY VC, THOMPSON JA. Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis (letter to editor). Blood 1999: 94: 3273-3276.
31. KOBBE G, GERMING U, AIVADO M, et al. Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantation. Transplantation 2002: 74: 1198-1200.
32. WOOLFREY AE, NASH RA, SANDERS JE, OCHS HD, THOMSON B, STORB R. A nonmyeloablative regimen for induction of multi-lineage hematopoietic mixed donor-host chimerism in nonmalignant disorders. Blood 2000: 98(Part 1): 784a, 3390 (abstract).
33. GÜNGÖR T, CORBACIOGLU S, STORB R, SEGER RA. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of dyskeratosis congenita. Bone Marrow Transplant 2003: 31: 407-410.
34. GUARDIOLA P, KURRE P, VLAD A, et al. Effective graft-versus-leukaemia effect after allogeneic stem cell transplantation using reduced intensity preparative regimens in Fanconi anaemia (FA) patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Br J Haematol 2003: 122: 806-807.
35. IANNONE R, CASELLA JF, FUCHS EJ, et al. Results of minimally toxic non-myeloablative transplantation in patients with sickle cell anemia and β-thalassemia. Biol Blood Marrow Transplant 2003: 9: 519-528.
36. KURRE P, PULSIPHER M, WOOLFREY A, et al. Reduced toxicity and prompt engraftment following minimal conditioning of a patient with fanconi anemia undergoing hematopoietic stem cell transplantation from an HLA-matched unrelated donor. J Pediatr Hematol Oncol 2003: 25: 581-583.
37. HEGENBART U, LANGE T, LEIBLEIN S, et al. Successful treatment of severe paroxysmal nocturnal hemoglobinuria (PNH) with allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated donors after minimal conditioning. Blood 2001: 98(Suppl. 1): 675a, 2827 (abstract).